The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France
Crossref DOI link: https://doi.org/10.1007/s10198-019-01123-5
Published Online: 2019-10-24
Published Print: 2020-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
de Pouvourville, GĂ©rard http://orcid.org/0000-0002-5941-6823
Blin, Patrick
Karam, Pierre
Funding for this research was provided by:
Boehringer Ingelheim Fonds (316097 ADA -07/24/2017)
Text and Data Mining valid from 2019-10-24
Version of Record valid from 2019-10-24
Article History
Received: 16 December 2018
Accepted: 2 October 2019
First Online: 24 October 2019